Clinical trial
Investigating the Potential Role of Aerosolized Retinoic Acid, a Potent Vitamin A Metabolite for Treating COVID-19 Anosmia and Retinoic Acid Insufficiency .A Novel Approach for Regaining Sense of Smell.
NCT05002530 is registered in ClinicalTrials.gov with Kafrelsheikh University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Investigating the Potential Role of Aerosolized Retinoic Acid, a Potent Vitamin A Metabolite for Treating COVID-19 Anosmia and Retinoic Acid Insufficiency .A Novel Approach for Regaining Sense of Smell.
- Lead sponsor
- Kafrelsheikh University
- Phase
- Phase 4
- Overall status
- Unknown status
- Start date
- November 30, 2021
- Completion date
- January 31, 2022
- Enrollment
- 10,000 (estimated)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.
post covid-19 anosmia (loss of smell)